Resting heart rate variability and exercise capacity in Type 1 diabetes

Luke C. Wilson1,2, Karen C. Peebles3,4,5, Neil A. Hoye1, Patrick Manning1, Catherine Sheat1, Michael J. A. Williams1,2, Gerard T. Wilkins1,2, Genevieve A. Wilson1,2 & James C. Baldi1,2

1 Department of Medicine, University of Otago, Dunedin, New Zealand
2 HeartOtago, University of Otago, Dunedin, New Zealand
3 Cardiovascular Systems Laboratory, University of Otago, Wellington, New Zealand
4 Department of Physiology, University of Otago, Dunedin, New Zealand
5 Department of Health Professions, Faculty of Medicine and Health Sciences, Macquarie University, New South Wales, Australia

Keywords
Autonomic nervous system, HR reserve, type 1 Diabetes, VO2max.

Correspondence
Luke Wilson, Department of Medicine, 9th Floor, Dunedin Hospital, Great King Street, Dunedin 9016, New Zealand.
Tel: +64 34709993
Fax: +64 34709916
E-mail: Luke.wilson@otago.ac.nz

Funding Information
This study was funded by the H.S. and J.C. Anderson Charitable Trust obtained by J.C. Baldi.

Received: 16 November 2016; Revised: 16 March 2017; Accepted: 18 March 2017
doi: 10.14814/phy2.13248
Physiol Rep, 5 (8), 2017, e13248, doi:10.14814/phy2.13248

Abstract
People with type 1 diabetes (T1D) have lower exercise capacity (VO2max) than their age-matched nondiabetic counterparts (CON), which might be related to cardiac autonomic dysfunction. We examined whether Heart Rate Variability (HRV; indicator of cardiac autonomic modulation) was associated with exercise capacity in those with and without T1D. Twenty-three participants with uncomplicated T1D and 17 matched CON were recruited. Heart rate (HR; ECG), blood pressure (BP; finger photo-plethysmography), and respiratory rate (respiratory belt) were measured during baseline, paced-breathing and clinical autonomic reflex tests (CARTs); deep breathing, lying-to-stand, and Valsalva maneuver. Baseline and paced-breathing ECG were analyzed for HRV (frequency-domain). Exercise capacity was determined during an incremental cycle ergometer test while VO2, 12-lead ECG, and BP were measured. In uncomplicated T1D, resting HR was elevated and resting HRV metrics were reduced, indicative of altered cardiac parasympathetic modulation; this was generally undetected by the CARTs. However, BP and plasma catecholamines were not different between groups. In T1D, VO2max tended to be lower (P = 0.07) and HR reserve was lower (P < 0.01). Resting Total Power (TP) had stronger positive associations with VO2max (R2 ≥ 0.3) than all other traditional indicators such as age, resting HR, and self-reported exercise (R2 = 0.042–0.3) in both T1D and CON. Alterations in cardiac autonomic modulation are an early manifestation of uncomplicated T1D. Total Power was associated with reduced exercise capacity regardless of group, and these associations were generally stronger than traditional indicators.

Introduction
People with type 1 diabetes (T1D) have poorer exercise capacity than their aged-matched nondiabetic counterparts (Hilsted et al. 1979; Kahn et al. 1986; Roy et al. 1989; Hagglund et al. 2012; Peltonen et al. 2012; Koponen et al. 2013; Rissanen et al. 2015). In nondiabetics, exercise capacity is associated with exercise capacity (see review (Hautala et al. 2009)). It is common for T1D to suffer from cardiac autonomic dysfunction and/or neuropathy (i.e., changes in sympathetic (SNS) or parasympathetic (PNS) modulation or both (Vinik and Ziegler 2007; Pop-Busui 2010; Karayannis et al. 2012; Vinik et al. 2013)), and this may contribute to poorer exercise capacity. Common manifestations of cardiac autonomic dysfunction and/or neuropathy are an elevation in resting heart rate (HR) and a reduction in maximal (max) HR, hence a lower HR response to exercise (i.e., reduced HR reserve). Previous studies report that exercise capacity is significantly reduced in those with...
“complicated” T1D (i.e., with concomitant diabetes-related chronic disease) and known cardiac autonomic neuropathy (Hilsted et al. 1979; Kahn et al. 1986; Roy et al. 1989). However, cardiac autonomic damage is a progressive phenomenon and subclinical manifestations such as an imbalance of cardiac autonomic modulation can occur in the early stages of T1D, with prognostic implications (Vinik and Ziegler 2007; Pop-Busui 2010; Karayannis et al. 2012; Vinik et al. 2013). To date little is known about the association between cardiac autonomic modulation and exercise capacity in those with uncomplicated T1D (i.e., free from known diabetes-related chronic disease). Indeed understanding whether there is a relationship between impaired cardiac autonomic modulation and reduced exercise capacity may offer further prognostic utility in the T1D population.

Resting HR and analysis of its variability (HRV, Heart rate variability) are commonly used in the clinical and research areas to gain insight into cardiac autonomic modulation. HRV, measured for a short time period in the frequency-domain, yields four inter-related metrics of variability, which are reported as power. Specifically, Total Power (TP), High Frequency Power (HF), and Low Frequency Power (LF), and the LF/HF ratio are quantified (Task Force, 1996). Care needs to be taken when interpreting these metrics, as there is controversy as to what they represent (Eckberg 1997; Parati et al. 2006; Reyes del Paso et al. 2013; Joyner 2016). Nevertheless, advantages of this technique are that it is non-invasive, requires minimal patient input and in the general sense provides a prognostic insight into global cardiovascular health (Task Force, 1996; Thayer and Lane 2007; Reyes del Paso et al. 2013). Specifically, lower TP, HF and LF are associated with increased cardiovascular morbidity and mortality in the general (Tsuji et al. 1994, Task Force, 1996; Thayer and Lane 2007; Joyner 2016) and T1D populations (Colhoun et al. 2001; Vinik and Ziegler 2007). Indeed HRV analysis has recently been recommended as an adjuvant to the traditional clinical autonomic reflex tests (CARTs), in T1D (Bernardi et al. 2011; Karayannis et al. 2012).

To the best of our knowledge only one study has investigated whether HRV is associated with reduced exercise capacity in patients with uncomplicated T1D. Hagglund et al. (2012) investigated HRV in 10 T1D and found no association between resting HRV metrics and VO2max in this group. However, the absence of association was assessed with a small sample size (n = 10) and with second derivative frequency-domain metric (i.e., derived from TP); HF power. Accordingly, the relationship between resting HRV and exercise capacity in T1D requires further investigation.

Hence, the aim of this study was to examine resting HRV and whether it was associated with exercise capacity in people with and without uncomplicated T1D. Emphasis was placed on TP as it is a global indicator of HRV (Task Force, 1996, Bernardi et al. 2011). We hypothesized that resting TP would be positively associated with exercise capacity in people with or without uncomplicated T1D. Associations between exercise capacity variables and the LF/HF ratio, a controversial reflection of autonomic balance (Parati et al. 2006) were also considered.

Methods

The study was approved by the Lower South Health and Disability Ethics Committee, New Zealand, and complied with the Declaration of Helsinki. All participants gave written informed consent. In participants with T1D this included access to their clinical records for their latest HbA1c measurement. The latter reflects average glycaemia over the preceding 3 months.

Participants

Participants comprised 23 T1D and matched 17 nondiabetics (CON; see Results for details of matching). The T1D participants were recruited from the Endocrinology Clinic at the Dunedin Public Hospital, and the CON participants were recruited from the local community. Prior to acceptance into the study participants completed a health screening questionnaire [documenting: smoking history, diagnosis of diabetes, self-reported exercise (i.e., hours of physical activity per week), medication use, and comorbidities]. Exclusion criteria were known diabetic neuropathy (autonomic and peripheral) and nephropathy, as well as cardiovascular, cerebrovascular, and respiratory disease, and medications which affect HR (i.e., beta-blockers).

Experimental design

All experiments were conducted within the Dunedin Public Hospital. Participants arrived at the laboratory between 8:00 AM and 2:00 PM, with each experimental session lasting 2–3 h, ~2 h after eating a non-standardized light meal, and having abstained from caffeine, alcohol, and heavy exercise for at least 12 h (Bernardi et al. 2011; Spallone et al. 2011). The experimental protocol comprised two successive parts, Part 1 always preceded Part 2, due to the aforementioned standardization requirements. Part 1 (~1 h) involved measurement of baseline and paced breathing parameters and CARTs, generally ordered from those that cause the smallest physiological perturbations to the largest (see below). This was conducted in a research laboratory. Part 2 involved a maximal exercise capacity test. This was conducted in a specialized clinical
laboratory, with standard emergency equipment. Participants voided their bladders before commencing the experimental protocol.

**Part 1: Measurement of resting and paced breathing parameters and CARTs**

Participants were instrumented in a supine position as follows. A 3-lead electrocardiograph [(ECG; Lead II position); FE132, ADInstruments, Dunedin, NZ] was used to measure heart rate (HR) and rhythm. Finger photoplethysmography (Finometer® MIDI, FMS, Finapres Medical Systems BV, the Netherlands) was used to measure beat-to-beat arterial blood pressure (BP). The finometer cuff was referenced to heart level and measurements were verified against manual sphygmomanometer (ADC DIAGNOSTIX™ 972, ADC, NY) measurements, taken on the contralateral arm. A respiratory belt transducer (MTL1132, ADInstruments, Dunedin, NZ) was placed around the chest to detect breathing frequency. All data these signals were recorded continuously at 1 kHz via an analog-to-digital converter (Powerlab/3508/P; ADInstruments, Dunedin, NZ) and stored for offline analysis.

**Baseline parameters**

After acclimation to the equipment (~15 min supine rest) 5 min of baseline (resting) data was collected. Participants were instructed not to speak and to minimize movement during data collection. Baseline HR, breathing frequency and BP were determined by averaging the final 3 min of the baseline recording. In addition, the ECG data was used in HRV analysis (see below).

**Paced breathing**

Participants performed 5 min of paced breathing guided by a metronome at a rate of 15 br/min (2 sec inspiration, 2 sec expiration). During which participants were instructed not to increase their breathing depth (i.e., avoid hyperventilation). Breathing frequency was controlled at the prescribed rate in both groups (T1D: 14.9 ± 0.5 br/min and CON: 14.9 ± 0.5 br/min). The final 3 min of paced breathing ECG data was also used in HRV analysis.

**HRV analysis**

HRV analysis was performed in accordance with the Task Force of the European Society of Pacing and Electrophysiology (Task Force, 1996). The ECG was screened for artefacts, and frequency-domain HRV was determined using the Fast-Fourier Transform method (HRV module v1.4.2, ADInstruments, Dunedin, NZ). The HRV metrics obtained (in msec²) were TP (0–0.4 Hz) and its derivatives, Very-Low Frequency Power (VLF: 0–0.04 Hz), LF (0.04–0.15 Hz), and HF (0.15–0.4 Hz). The LF/HF ratio was then calculated. In this study, the VLF was not presented as it is unreliable in short term recordings (Task Force, 1996). Time-domain HRV was not determined, as there is a concern with its sensitivity and reproducibility with the shorter collection times used within this study (Task Force, 1996).

**CARTs**

Four standard clinical tests and analysis approaches were used to assess cardiovascular autonomic modulation and a composite criteria (see below) of abnormal values/responses were used to detect the possible presence cardiovascular autonomic dysfunction as detailed in the current consensus statements (see; (Bernardi et al. 2011; Spallone et al. 2011)). These were the assessment of resting HR, the response to deep breathing, lying-to-standing, and a Valsalva maneuver which are detailed below. Each of the tests (or repeat tests) were separated by at least 5 min for recovery (Bernardi et al. 2011; Spallone et al. 2011). (1) Resting HR, which was obtained during baseline for each participant, was screened for the presence (abnormal) or absence of tachycardia (defined as HR > 100 b/min). (2) Deep breathing and the magnitude of the respiratory-evoked HR change. Participants guided by a metronome were instructed to breathe 6 br/min (5 sec inspiration, 5 sec expiration) for 1 min, to a depth that equaled their vital capacities. This occurred twice separated with the recovery period. For analysis, the highest HR (occurs during inspiration) and the lowest HR (occurs during expiration) were determined separately for each breath and across each trial. Then the maximum change in HR was determined by difference between the mean of the three highest and lowest HR’s in each trial. The trial which was determined to have the maximal HR response and optimal breathing control was selected, and a HR change of <10 b/min was taken to reflect abnormal cardiac autonomic modulation. (3) Supine-to-standing and the posture change induced HR and BP response. After 1 min collection of supine data, participants were instructed to rapidly stand from a supine position, and remain there as still as possible for 3 min, from this two parameters were determined. (a) the 30:15 ratio for the HR response where the longest R-R interval (20–40th beats) is divided by the shortest R-R interval (5–25th beats) after standing. For each participant the 30:15 ratio was compared to age-adjusted normative values to reflect normal or abnormal cardiac autonomic modulation (Spallone et al. 2011); and (b) the systolic BP response to
standing, where the systolic BP (average for 1 min) following ≥ 2 min of standing was subtracted from the mean systolic BP from the preceding supine period. A fall in systolic BP of > 30 mm Hg was taken to reflect cardiovascular autonomic modulation. (4) The Valsalva maneuver and the alterations in intrathoracic pressure to evoke changes in HR. Participants in the supine position, were instructed to breathe in as deeply as possible before force-fully exhaling into a closed mouthpiece to generate an expiratory pressure of 40 mm Hg for 15 sec. The time (T1D: 16.7 ± 0.7 sec and CON: 16.7 ± 1.5 sec) of and the generation of expiratory pressure (T1D: 39 ± 8 mm Hg and CON: 39 ± 6 mm Hg) was measured by a calibrated pressure transducer (Model: P-23 ID, Statham Instruments, Inc). Following the maneuver, the participants were instructed to resume normal breathing. The Valsalva maneuver was repeated at least once, with the maneuver closest to the fore mentioned time and pressure criteria and with the most consistent pressure generation selected for analysis. The Valsalva ratio was determined as the shortest R-R interval during the maneuver divided by the longest R-R interval within a minute following the maneuver. The values obtained for each participant were compared to age-adjusted normative values to reflect normal or abnormal cardiac autonomic modulation (Spallone et al. 2011).

The number of abnormal results denoted possible cardiovascular autonomic dysfunction and/or neuropathy. Specifically: (1) one abnormal HR test suggested early cardiovascular autonomic dysfunction and/or neuropathy; (2) two or three abnormal HR tests confirmed cardiovascular autonomic dysfunction and/or neuropathy; (3) two or three abnormal HR tests plus an abnormal systolic BP response to standing to reflected severe involvement of cardiovascular autonomic control (Bernardi et al. 2011; Spallone et al. 2011).

**Part 2: Maximal exercise capacity**

Prior to maximal exercise testing participants had a cannula inserted in an antecubital vein, and were then instrumented with a standard diagnostic 12-lead ECG. Then they rested (supine) for 20 min and before a 10 mL blood sample was taken (following ~3 mL discarded), the sample was taken into chilled EDTA vacutainers and placed on ice (~5 min) before processing (see below). The cannula was then flushed with sterile normal saline (0.9% NaCl) to maintain patency. Participants then performed a maximal incremental exercise test on a cycle ergometer (Model: E100 P, COSMED), while BP, ECG and metabolic variables [\(\dot{V}O_2\), \(\dot{V}CO_2\), and R (i.e., \(\dot{V}CO_2/\dot{V}O_2\); Quark CPET, COSMED)] were monitored and measured at each stage. The protocol started at 50 W and increased at a magnitude of 25 or 50 W (individualized for each participant) every 2 min, until volitional exhaustion. In the 30 sec prior to volitional exhaustion, a 10 mL exercise blood sample (using the procedure detailed above) was acquired from each participant.

A successful exercise test which allowed for determination of \(\dot{V}O_{2\text{max}}\) was indicated by at least two of the following criteria; an R value of ≥ 1.1; a max HR ≥ 85% of age-predicted max (220 – age); a plateau in \(\dot{O}_2\) consumption (<150 mL/min) despite an increase in workload; and a failure to maintain the workload (Edvardsen et al. 2014). The \(\dot{V}O_{2\text{max}}\) was determined as the mean the three highest consecutive \(\dot{V}O_2\) values, max HR as the highest obtained HR, and then HR reserve was calculated as max HR – resting HR (obtained in the analysis of part (1). In addition, the maximum breathing frequency, tidal volume, ventilation and R, were recorded. T1D participants had their blood glucose checked prior to and after exercise.

**Blood analysis**

The blood samples (rest and exercise) were centrifuged separately at 1500 G for 15 min at 4°C, the plasma extracted, and frozen and stored in a −80°C freezer for later batch analysis. Plasma noradrenaline and adrenaline was extracted using aluminum oxide technique and analyzed using high-performance liquid chromatography with electrochemical detection (Eisenhofer et al. 1986).

**Statistical analysis**

All statistical procedures were carried out using IBM SPSS (Version 21 for Microsoft Windows, IBM Corporation, Armonk, New York). All data were checked for normality using the Shapiro–Wilks test; data were log transformed if normality was violated, this occurred for most HRV metrics and the plasma catecholamines (Figs. 1 and 2). Differences in participant demographics, baseline and exercising variables between groups were compared using independent t-tests. The HRV metrics (baseline and paced breathing conditions) and plasma catecholamines (rest and exercise) were compared using mixed two-way repeated measures ANOVA [factors: condition and group (T1D vs. CON)]. As no significant interactions (i.e., condition × group) were identified, Post Hoc analysis was not performed, and the alpha values for condition, group, and interaction are presented in Figures 1 and 2. Separate Pearson’s correlations and linear regressions were used to determine the association between the TP (determined at baseline) and the individual indicators of exercise capacity; \(\dot{V}O_{2\text{max}}\), HR reserve and max HR in both T1D and CON. The HR reserve and maximum HR were model in
addition to $\dot{V}O_2_{\text{max}}$ as diabetes is known to impact the HR response to exercise. The LF/HF ratio was also considered with the same approach as TP. In all Pearson’s and linear regression models the residuals were normally distributed with untransformed units, allowing for the use of these parametric models. In primary analysis three
CON participants with exceedingly high TP (>11,000 msec²) were determined to be influential cases with Cook’s distance values of between 1.2 and 79 (value > 1 being of concern). These participants were excluded from the presented secondary analysis which involved TP and the LF/HF ratio. In addition to the HRV metrics, other traditional (i.e., age, resting HR, and self-reported exercise) and clinical variables (i.e., HbA1c) that would be available in clinical visits to exercise capacity were explored. Select linear regression analyses were interpreted (within the discussion) by multiplying the slope (β) of interest by the standard deviation of the regressed independent variable (i.e., TP), which calculates the associated change in the dependent variable (i.e., \( \dot{V}O_{2max} \)). An \( P < 0.05 \) was set to signify significance, and the data is presented as mean ± SD.

**Results**

All 40 participants completed the study. Table 1 shows the participant characteristics, the T1D and CON were sex-, age-, mass-, height- and self-reported exercise-matched. Although T1D had a slightly greater BMI than CON (\( P = 0.06 \)), both groups were within the same BMI range (i.e., classified overweight). Participants with T1D were diagnosed with T1D at a mean age of 16 year old (range: 1–42 year). The mean duration of T1D was 15 year (range: 1–46 year). All T1D were receiving insulin therapy (7 via insulin pump) and their mean HbA1c was ~68 mmol/mol (~8.4%). Supplementary medical therapies included antidepressants (in 3 T1D and 1 CON), statins (in 4 T1D), ACE inhibitors (in 2 T1D), acetylsalicylic acid (in 1 T1D), omeprazole (in 1 T1D), antiepileptic (in 1 CON), and combined oral contraceptive (in 1 CON). All participants with T1D had no known significant microvascular complications; two participants had small changes in urine albumin. However, this may reflect variable glycemic control rather than actual diabetic nephropathy.

**Baseline parameters and CARTS**

T1D had higher resting HR than CON (Table 2). However, resting BP, breathing frequency and catecholamines were similar between groups (Table 2 and Fig. 1). Three T1D participants had one abnormal CART result which was a depressed HR response to deep breathing. None of the remaining T1D or CON participants had any abnormal responses to the CARTs.

**HRV**

The HRV metrics during baseline and paced breathing are shown in Figure 2. No significant interactions were found (Condition x Group), therefore Post Hoc testing was not performed. The T1D when compared to CON, had lower TP, LF power, and HF power, but not LF/HF ratio (Fig. 2). Regardless of group, most HRV metrics were lower during the paced than the baseline condition.

### Table 2. Baseline and exercise variables.

| Variable                  | T1D (n = 23) | CON (n = 17) | P value |
|---------------------------|--------------|--------------|---------|
| Resting HR (bpm)          | 74 ± 11      | 65 ± 9       | <0.01   |
| Max HR (bpm)              | 180 ± 13     | 186 ± 11     | 0.14    |
| HR Reserve (bpm)          | 106 ± 16     | 122 ± 13     | <0.01   |
| Resting SBP (mm Hg)       | 123 ± 14     | 122 ± 10     | 0.77    |
| Resting DBP (mm Hg)       | 75 ± 11      | 74 ± 11      | 0.75    |
| Resting MBP (mm Hg)       | 91 ± 11      | 89 ± 9       | 0.73    |
| Resting breathing frequency (br/min) | 15 ± 5 | 13 ± 4 | 0.30 |
| Max breathing frequency (br/min) | 45 ± 7 | 54 ± 9 | <0.01 |
| Max tidal volume (L)      | 2.6 ± 0.7    | 2.8 ± 0.8    | 0.45    |
| Max ventilation (L/min)   | 110 ± 32     | 132 ± 39     | 0.05    |
| \( \dot{V}O_{2max} \) (mL/min/kg) | 32 ± 9 | 37 ± 9 | 0.07 |
| Max R-Value               | 1.29 ± 0.09  | 1.25 ± 0.08  | 0.12    |
| Time to exhaustion (min)  | 8.7 ± 2.6    | 9.9 ± 2.0    | 0.14    |
| Max workload (W)          | 186 ± 64     | 219 ± 57     | 0.06    |
| Normalized max workload (W/kg) | 2.3 ± 0.7 | 2.9 ± 0.7 | 0.01 |

Values are presented as means ± SD.

Resting HR, resting heart rate; max HR, maximum heart rate; HR reserve, heart rate reserve; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean arterial blood pressure; \( \dot{V}O_{2max} \), maximal aerobic capacity; max R-value, maximum respiratory exchange ratio.

---

BMI, Body mass index; HbA1c, glycated hemoglobin.

Values are presented as mean ± SD.

\(^{1}\)Chi-squared test used for significance testing.
Exercise capacity

All participants met the criteria for determination of \( \dot{V}O_2\text{max} \). In T1D, \( \dot{V}O_2\text{max} \) tended to be (−14%) lower than in CON \((P = 0.07\), Table 2). Some determinants of \( \dot{V}O_2\text{max} \) were different between groups. In T1D, HR reserve was ~13% lower than CON as a result of a significantly higher resting HR and a non-significant reduction in max HR (Table 2). Additionally, in T1D max ventilation was ~17% lower, due a reduced max breathing frequency, as max tidal volume was not different between groups (Table 2). However the exercise levels of catecholamines and their change in response to exercise were not different between groups (Fig. 1).

Associations with exercise capacity

Separate correlation and regression analysis between exercise capacity (\( \dot{V}O_2\text{max} \), HR reserve and max HR), HRV metrics (TP and the LF/HF ratio) and other traditional and clinical variables are shown in Table 3. Irrespective of group the relationship between TP and \( \dot{V}O_2\text{max} \) was stronger than the other modeled independent variables. Specifically, TP was positively associated with \( \dot{V}O_2\text{max} \) (T1D and CON), HR reserve (T1D and CON) and Max HR (T1D only). The \( R^2 \) between TP and \( \dot{V}O_2\text{max} \) was 0.30 and 0.37 for T1D and CON, respectively (Table 3 and Fig. 3). By contrast the LF/HF ratio was not associated with \( \dot{V}O_2\text{max} \), HR reserve or max HR in either group. Although T1D duration was associated with max HR \((R^2 = 0.23\), HbA1c was not related to \( \dot{V}O_2\text{max} \), HR reserve, or max HR. Irrespective of group, there were no associations between self-reported exercise and exercise capacity.

Discussion

We examined whether resting cardiac autonomic modulation, characterized by HRV, was associated with exercise capacity in people with and without uncomplicated T1D.

### Table 3. Associations with exercise capacity variables.

| Dependent variable       | Independent variable | T1D                     | CON                      |
|--------------------------|----------------------|-------------------------|-------------------------|
| \( \dot{V}O_2\text{max} \) (mL/min/kg) | TP (msec²)           | 0.30 \^1                | 0.37 \^1                |
|                          | LF/HF ratio (au)     | 0.004                   | 0.002                   |
|                          | Age (year)           | 0.18 \^1               | 0.30 \^1               |
|                          | Resting HR (bpm)     | 0.12                    | 0.15                    |
|                          | BMI (kg/m²)          | 0.22 \^1               | 0.12                    |
|                          | Self-reported exercise (h) | 0.048                  | 0.12                    |
|                          | T1D duration (year)  | 0.02                    | –                       |
|                          | HbA1c (mmol/mol)     | 0.0650                  | –                       |
| HR Reserve (bpm)         | TP (msec²)           | 0.41 \^1               | 0.36 \^1               |
|                          | LF/HF ratio (au)     | 0.009                   | 0.002                   |
|                          | Age (year)           | 0.10                    | 0.42 \^1               |
|                          | Resting HR (bpm)     | 0.35 \^1               | 0.24 \^1               |
|                          | BMI (kg/m²)          | 0.09                    | 0.05                    |
|                          | Self-reported exercise (h) | 0.004                  | 0.040                   |
|                          | T1D duration (year)  | 0.05                    | –                       |
|                          | HbA1c (mmol/mol)     | 0.0780                  | –                       |
| Max HR (bpm)             | TP (msec²)           | 0.40 \^1               | 0.08                    |
|                          | LF/HF ratio (au)     | 0.002                   | 0.001                   |
|                          | Age (year)           | 0.53 \^1               | 0.66 \^1               |
|                          | Resting HR (bpm)     | 0.01                    | 0.04                    |
|                          | BMI (kg/m²)          | 0.08                    | 0.04                    |
|                          | Self-reported exercise (h) | 0.040                  | 0.013                   |
|                          | T1D duration (year)  | 0.23 \^1               | –                       |
|                          | HbA1c (mmol/mol)     | 0.0001                  | –                       |

Dependent variables: \( \dot{V}O_2\text{max} \); maximum aerobic capacity; HR reserve, heart rate reserve; Max HR, maximum heart rate. Independent variables; TP, total power; LF/HF ratio, low frequency power to high frequency power ratio; resting HR, resting heart rate; BMI, body mass index; T1D; Type 1 diabetes, and HbA1c, glycated hemoglobin. The \( \beta \) values are presented as the mean slope ± SD of the slope.

\(^{1}\)Significant association \((P < 0.05\), which are in bolded text. TP and LF/HF ratio were derived from the baseline condition. 

© 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.
The main findings were as follows. First, despite a priori selection for uncomplicated T1D (i.e., free from known diabetes-related chronic disease), subtle changes in resting cardiac autonomic modulation were evident in this population. These changes were not revealed using traditional diagnostic criteria (i.e., 2 or more abnormal CARTs) but were evident from resting HR (sub-clinical change) and frequency-domain analyses of resting HRV. Specifically, the T1D had higher resting HR and lower HRV (reductions in TP, LF and HF, but not LF/HF ratio) than matched CON. Second, the T1D tended to have a lower exercise capacity (HR reserve and near significant reductions in TP, LF and HF, but not LF/HF ratio) than matched CON, as expected. Third, in accordance with our hypothesis TP was positively associated with exercise capacity in both groups. Indeed the attributed variance for TP was greater than other measures in uncomplicated T1D compared to CON. These changes are commonly observed across the spectrum of T1D (Colhoun et al. 2001; Vinik and Ziegler 2007). Such changes are used to highlight subtle early variation in cardiac autonomic modulation in patients with diabetes (Bernardi et al. 2011; Spallone et al. 2011), despite resting HRV being influenced by a number of factors including cardiorespiratory fitness. There appears to be a diabetes specific effect on resting HRV, as reductions in resting HRV metrics are apparent in newly diagnosed T1D without a decline in cardiorespiratory fitness (Röhlöng et al. 2017). Nevertheless, some of the controversy regarding frequency-domain HRV analysis warrants consideration.

In the past, it has been argued that the LF band and the LF/HF ratio reflect cardiac SNS modulation and the balance of cardiac autonomic modulation, respectively (Eckberg 1997; Parati et al. 2006; Reyes del Paso et al. 2013; Joyner 2016). However, there is increasing recognition that the resting HRV metrics are more reflective of cardiac PNS than cardiac SNS modulation (Reyes del Paso et al. 2013; Joyner 2016). In line with this notion are the following three points: (1) high-dose administration of the muscarinic receptor blocker, atropine (a PNS antagonist), abolishes most, if not all spectral power within all bands (TP, LF, and HF) (Eckberg 1997; Reyes del Paso et al. 2013; Joyner 2016); (2) SNS blockade does not influence the power within the LF band, whether it is presented in absolute or normalized units (Eckberg 1997;
The observed reduction in resting TP tended to be inversely associated with diabetes duration ($R^2 = 0.14; P = 0.08$), but not HbA$_1c$ ($R^2 < 0.01; P = 0.92$), and the elevation in resting HR tended to be positively associated with HbA$_1c$ ($R^2 = 0.16; P = 0.06$) but not diabetes duration ($R^2 = 0.06; P = 0.27$) in this study. Although speculative, cardiovascular autonomic dysfunction and neuropathy seem to mirror the development of peripheral neuropathy starting distally and progressing proximally (Pop-Busui 2010). As the vagus nerve is the longest autonomic nerve and it is responsible for ~75% of all PNS activity, it stands to reason that early manifestation of cardiovascular dysfunction and/or neuropathy are associated with the PNS (Pop-Busui 2010). Our participants with T1D had diabetes for at least a year, were receiving insulin therapy, and had an elevated HbA$_1c$. Therefore it is conceivable that an effect on cardiac PNS modulation may have occurred in our uncomplicated T1D cohort.

**Effect of uncomplicated T1D on exercise capacity**

We found that our uncomplicated T1D had blunted exercise capacity, which is common finding across the spectrum of T1D (Hilsted et al. 1979; Kahn et al. 1986; Roy et al. 1989; Hagglund et al. 2012; Peltonen et al. 2012; Koponen et al. 2013; Rissanen et al. 2015). Specifically in T1D, $\dot{V}_{O_2\text{max}}$ tended ($P = 0.07$) to be reduced by ~5 mL/min/Kg, which equates to ~1.4 metabolic equivalents (METs). The Fick equation states that a change in $\dot{V}_{O_2\text{max}}$ could arise from altered cardiac response, and/or peripheral extraction (arterial – venous $O_2$ difference). Peripheral oxygen extraction was not assessed in this study, however it is unlikely to contribute to the observed reduction in $\dot{V}_{O_2\text{max}}$ as peripheral oxygen extraction seems to be unaffected by T1D (Rissanen et al. 2015), despite lower oxidative capacity in muscles (Crowther et al. 2003). This then highlights the importance of the cardiac response contributing to $\dot{V}_{O_2\text{max}}$ and exercise tolerance. We found that HR reserve (i.e., reduced cardiac response) was ~13% lower in T1D. While HR reserve is not often quantified in T1D, the combination of elevated resting and lower max HR’s would cause the reduced HR reserve. We found that max HR in T1D was ~6 bpm lower though not significantly so ($P = 0.14$). Max HR generally seems to be unchanged with less complicated T1D (Baldi et al. 2010; Hagglund et al. 2012; Roberto et al. 2012; Koponen et al. 2013; Rissanen et al. 2015). The exercise level of plasma catecholamines and their responses exercise were not affect by T1D (Fig. 1), this has been previously observed (Nugent et al. 1997; Pop-Busui et al. 2004), and may indicate a similar global SNS response to exercise in uncomplicated T1D.

The cause(s) of a blunted exercise capacity in T1D are numerous and complex, a complete discussion or elucidation of these with further physiological testing are outside the scope of this study. However, exercise capacity in T1D is known to be affected by glycemic control (Baldi et al. 2010; Rissanen et al. 2015), cardiovascular autonomic dysfunction and/or neuropathy (Hilsted et al. 1979; Kahn et al. 1986; Roy et al. 1989), insulin resistance (Nadeau et al. 2010), and there are likely to be other factors. The level of HbA$_1c$ (range: 49–111 mmol/mol) was not associated with $\dot{V}_{O_2\text{max}}$ HR reserve, or max HR in uncomplicated T1D (Table 3), as previously reported
(Koponen et al. 2013). However, highly-trained T1D athletes with poorer glycemic control (mean HBA1c: ~62 mmol/mol vs. ~48 mmol/mol) had blunted VO2peak and peak HR (Baldi et al. 2010). It has since been suggested that appropriate glycemic control may independently increases exercise capacity in people with T1D (Baldi and Hofman 2010), which is not supported in this study. It is difficult to know why this study in non-athletes with uncomplicated contradicts these findings, and warrants further investigation.

**Associations of resting HRV with exercise capacity**

A focus of this study was to use the surrogate indicator of resting cardiac PNS modulation; TP and its separate associations to VO2max HR reserve and max HR in those with and without uncomplicated T1D to indicate exercise capacity. The associations between TP and the exercise capacity variables were stronger than traditional indicators such as age, resting HR, and self-reported exercise (Table 3). Specifically TP, which was reduced in our uncomplicated T1D, was associated with VO2max (T1D: $R^2 = 0.30$; & CON: $R^2 = 0.37$; Fig. 3) and HR reserve (T1D: $R^2 = 0.41$; & CON: $R^2 = 0.36$) in both T1D and CON, and max HR in T1D only ($R^2 = 0.40$; Table 3). A one standard deviation increase in TP (T1D: 1646 msec²; & CON: 1724 msec²) when multiplied by the slope ($\beta$) of the relationship was associated with an increase in VO2max of 4.9 mL/min/Kg in T1D and 5.2 mL/min/Kg in CON. Resting TP, regardless of group was associated with VO2max and HR reserve, indicating a continuum, where the participants with uncomplicated T1D are clustered with lower values of TP than CON (as highlighted in Fig. 3).

Despite associations between HRV metrics and exercise capacity in other populations (for review see (Hautala et al. 2009)), these are not well documented in uncomplicated T1D. Additionally, no studies have compared the strength of the associations between resting HRV metrics and exercise capacity to those between traditional and clinical indicators and exercise capacity. Our findings contradict Hagglund et al. (2012) who did not find an association in resting HRV and VO2max in their T1D group, despite both studies examining those whom seem to have uncomplicated T1D. However, there are two major differences between the studies. First, differences in statistical power (smaller sample in (Hagglund et al. 2012)); and second, the use of HF power (a second derivative frequency-domain metric) compared to TP in our study. In support of our findings a recently published study has reported associations between HRV metrics and exercise capacity in newly diagnosed T1D (Röhling et al. 2017).

Although speculative, an explanation of why a higher resting TP is associated with exercise capacity might be that it is reflective of a “healthier” cardiac autonomic system (Thayer and Lane 2007; Joyner and Green 2009). Commonly it is suggested that a strong and efficient PNS, but not an overactive SNS, is the basis of a well-balanced and adaptable cardiac autonomic system (Thayer and Lane 2007; Joyner and Green 2009). During exercise it is known that a shift in the balance of cardiac autonomic modulation (PNS:SNS ratio) from a ratio of ~4:1 at rest to ~1:4 at maximal exercise is required to increase HR (White and Raven 2014). Furthermore, relationships between aerobic exercise training and/or higher aerobic capacity and enhanced cardiac PNS modulation are known in healthy populations (Billman 2002; Buch et al. 2002; Carter et al. 2003; Hautala et al. 2009), and conversely, those who suffer from autonomic neuropathy have blunted exercise capacity (Hilsted et al. 1979; Kahn et al. 1986; Roy et al. 1989; Vinik and Ziegler 2007). Therefore it appears that a well-balanced resting cardiac autonomic nervous system with predominant PNS modulation is an important factor in influencing exercise capacity not only in CON but in uncomplicated T1D alike.

**Clinical implications**

Our study suggests that people with uncomplicated T1D can show subtle changes in autonomic nervous system function, which seem to be reflected in increased resting HR and reductions in frequency-domain HRV metrics, the latter which can be an additional test within a standard clinical visit. These subtle changes were not conclusively detected by the traditional CARTs, possibly indicating these tests may not be sensitive or specific enough to detect these alterations. The associations between TP and measures of exercise capacity in both T1D and CON were generally stronger that the other traditional and clinical indicators. Specifically a one standard deviation change in TP was associated with an increase in VO2max of 4.9 mL/min/Kg in T1D and 5.2 mL/min/Kg in CON. This indicates that TP, in people with and without uncomplicated T1D may provide useful information in regard to their capacity to exercise.

In summary, resting cardiac PNS modulation and exercise capacity were reduced with uncomplicated T1D. TP was positively associated with VO2max ($R^2 \geq 0.3$) in people with and without uncomplicated T1D and these relationships were stronger than other more commonly used traditional indicators, albeit within a modest cohort. This study highlights the importance of resting PNS modulation of the cardiovascular system in the adaptation to stressful stimuli like exercise.
Acknowledgement

The authors wish to thank Gavin Hendry for his assistance in the study, and the participants for volunteering for the study. We thank Professor Robert Walker for his guidance in the preparation and revision of this manuscript.

Conflict of Interest

The author(s) have no conflict of interest to declare.

Reference

Baldi, J. C., and P. L. Hofman. 2010. Does careful glycemic control improve aerobic capacity in subjects with type 1 diabetes? Exerc. Sport Sci. Rev. 38:161–167.

Baldi, J. C., N. A. Cassuto, W. T. Foxx-Lupo, C. M. Wheatley, and E. M. Snyder. 2010. Glycemic status affects cardiopulmonary exercise response in athletes with type I diabetes. Med. Sci. Sports Exerc. 42:1454–1459.

Bernardi, L., V. Spallone, M. Stevens, J. Hilstved, S. Frontoni, R. Pop-Busui, et al. 2011. Methods of investigation for cardiac autonomic dysfunction in human research studies. Diabetes Metab. Res. Rev. 27:654–664.

Billman, G. E. 2002. Aerobic exercise conditioning: a nonpharmacological antiarrhythmic intervention. J. Appl. Physiol. (1985) 92: 446–454.

Buch, A. N., J. H. Coote, and J. N. Townend. 2002. Mortality, cardiac vagal control and physical training–what’s the link? Exp. Physiol. 87:423–435.

Carter, J. B., E. W. Banister, and A. P. Blaber. 2003. Effect of endurance exercise on autonomic control of heart rate. Sports Med. 33:33–46.

Colhoun, H. M., D. P. Francis, M. B. Rubens, S. R. Underwood, and J. H. Fuller. 2001. The association of heart-rate variability with cardiovascular risk factors and coronary artery calcification: a study in type 1 diabetic patients and the general population. Diabetes Care 24:1108–1114.

Crowther, G. J., J. M. Milstein, S. A. Joubrias, M. J. Kushmerick, R. K. Gronka, and K. E. Conley. 2003. Altered energetic properties in skeletal muscle of men with well-controlled insulin-dependent (type 1) diabetes. Am. J. Physiol. Endocrinol. Metab. 284:E655–E662.

Eckberg, D. L. 1997. Sympathovagal balance: a critical appraisal. Circulation 96:3224–3232.

Edvardsen, E., E. Hem, and S. A. Anderssen. 2014. End criteria for reaching maximal oxygen uptake must be strict and adjusted to sex and age: a cross-sectional study. PLoS ONE 9:e85276.

Eisenhofer, G., D. S. Goldstein, R. Stull, H. R. Keiser, T. Sunderland, D. L. Murphy, et al. 1986. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin. Chem. 32:2030–2033.

Ewing, D. J., and B. F. Clarke. 1982. Diagnosis and management of diabetic autonomic neuropathy. Br. Med. J. (Clin Res Ed) 285:916–918.

Ewing, D. J., I. W. Campbell, and B. F. Clarke. 1980. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. Ann. Intern. Med. 92:308–311.

Hagglund, H., A. Uusitalo, J. E. Peltonen, A. S. Koponen, J. Aho, S. Tiinanen, et al. 2012. Cardiovascular autonomic nervous system function and aerobic capacity in type 1 diabetes. Front. Physiol. 3:356.

Hautala, A. J., A. M. Kiviniemi, and M. P. Tulppo. 2009. Individual responses to aerobic exercise: the role of the autonomic nervous system. Neurosci. Biobehav. Rev. 33:107–115.

Hilsted, J., H. Galbo, and N. J. Christensen. 1979. Impaired cardiovascular responses to graded exercise in diabetic autonomic neuropathy. Diabetes 28:313–319.

Ho, J. E., M. G. Larson, A. Ghorbani, S. Cheng, E. E. Coglianese, R. S. Vasan, et al. 2014. Long-term cardiovascular risks associated with an elevated heart rate: the Framingham Heart Study. J. Am. Heart Assoc. 3: e000668.

Joyner, M. J. 2016. Preclinical and clinical evaluation of autonomic function in humans. J. Physiol. 594:4009–4013.

Joyner, M. J., and D. J. Green. 2009. Exercise protects the cardiovascular system: effects beyond traditional risk factors. J. Physiol. 587:5551–5558.

Kahn, J. K., B. Zola, J. E. Juni, and A. I. Vinik. 1986. Decreased exercise heart rate and blood pressure response in diabetic subjects with cardiac autonomic neuropathy. Diabetes Care 9:389–394.

Karayannis, G., G. Giamouzis, D. V. Cokkinos, J. Skoularigis, and F. Triposkiadis. 2012. Diabetic cardiovascular autonomic neuropathy: clinical implications. Expert Rev. Cardiovasc. Ther. 10:747–765.

Kingwell, B. A., J. M. Thompson, D. M. Kaye, G. A. McPherson, G. L. Jennings, and M. D. Eder. 1994. Heart rate spectral analysis, cardiac norepinephrine spillover, and muscle sympathetic nerve activity during human sympathetic nervous activation and failure. Circulation 90:234–240.

Koponen, A. S., J. E. Peltonen, M. K. Paivinen, J. M. Aho, H. J. Hagglund, A. L. Uusitalo, et al. 2013. Low total haemoglobin mass, blood volume and aerobic capacity in men with type 1 diabetes. Eur. J. Appl. Physiol. 113:1181–1188.

Nadeau, K. J., J. G. Regensteiner, T. A. Bauer, M. S. Brown, J. L. Dorosz, A. Hull, et al. 2010. Insulin resistance in adolescents with type 1 diabetes and its relationship to...
cardiovascular function. J. Clin. Endocrinol. Metab. 95:513–521.
Nugent, A. M., I. C. Steele, F. al-Modaris, S. Vallely, A. Moore, N. P. Campbell, et al. 1997. Exercise responses in patients with IDDM. Diabetes Care 20:1814–1821.
Parati, G., G. Mancia, M. Di Rienzo, and P. Castiglioni. 2006. Point: cardiovascular variability is/is not an index of autonomic control of circulation. J. Appl. Physiol. (1985) 101:676–678, discussion 681-2.
Peltonen, J. E., A. S. Koponen, K. Pullinen, H. Hagglund, J. M. Aho, H. Kyrolainen, et al. 2012. Alveolar gas exchange and tissue deoxygenation during exercise in type 1 diabetes patients and healthy controls. Respir. Physiol. Neurobiol. 181:267–276.
Pop-Busui, R. 2010. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 33:434–441.
Pop-Busui, R., I. Kirkwood, H. Schmid, V. Marinescu, J. Schroeder, D. Larkin, et al. 2004. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J. Am. Coll. Cardiol. 44:2368–2374.
Reyes del Paso, G. A., W. Langewitz, L. J. Mulder, A. van Roon, and S. Duschek. 2013. The utility of low frequency heart rate variability as an index of sympathetic cardiac tone: a review with emphasis on a reanalysis of previous studies. Psychophysiology 50:477–487.
Rissanen, A. P. E., H. O. Tikkanen, A. S. Koponen, J. M. Aho, and J. E. Peltonen. 2015. Central and Peripheral Cardiovascular Impairments Limit VO2peak in Type 1 Diabetes. Med. Sci. Sports Exerc. 47:223–230.
Roberto, S., E. Marongiu, M. Pinna, L. Angius, S. Olla, P. Bassareo, et al. 2012. Altered hemodynamics during muscle metaboreflex in young type 1 diabetes patients. J. Appl. Physiol. (1985) 113:1323–1331.
Röhling, M., A. Strom, G. Bönhof, S. Püttgen, K. Bódis, K. Müssig, et al. 2017. Differential patterns of impaired cardiorespiratory fitness and cardiac autonomic dysfunction in recently diagnosed type 1 and type 2 diabetes. Diabetes Care 40:246–252.
Roy, T. M., H. R. Peterson, H. L. Snider, J. Cyrus, V. L. Broadstone, R. D. Fell, et al. 1989. Autonomic influence on cardiovascular performance in diabetic subjects. Am. J. Med. 87:382–388.
Spallone, V., D. Ziegler, R. Freeman, L. Bernardi, S. Frontoni, R. Pop-Busui, et al. 2011. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab. Res. Rev. 27:639–653.
Task Force. 1996. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93:1043–1065.
Thayer, J. F., and R. D. Lane. 2007. The role of vagal function in the risk for cardiovascular disease and mortality. Biol. Psychol. 74:224–242.
Tsuij, H., F. J. Jr Venditti, E. S. Manders, J. C. Evans, M. G. Larson, C. L. Feldman, et al. 1994. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation 90:878–883.
Vinik, A. I., and D. Ziegler. 2007. Diabetic cardiovascular autonomic neuropathy. Circulation 115:387–397.
Vinik, A. I., T. Erbas, and C. M. Casellini. 2013. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J. Diabetes Investig. 4:4–18.
White, D. W., and P. B. Raven. 2014. Autonomic neural control of heart rate during dynamic exercise: revisited. J. Physiol. 592:2491–2500.